指南与共识区域麻醉与超声术前评估与围术期医学

依诺肝素治疗后抗Xa活性残留与ASRA抗凝指南的再思考

Residual Enoxaparin Activity, Anti-Xa Levels, and Concerns About the American Society of Regional Anesthesia and Pain Medicine Anticoagulation Guidelines.
指南 / 共识 · Reg Anesth Pain Med · 2017-01-01

该研究关注ASRA指南推荐的治疗剂量依诺肝素后至少24小时再行椎管内操作,但临床发现抗Xa水平常仍升高。在择期手术患者中评估抗Xa活性,尽管几乎普遍符合ASRA指南(1例在23.25小时采血),19例中11例抗Xa活性升高。提示治疗剂量依诺肝素后显著抗凝活性可能持续超过24小时,当前基于时间的ASRA推荐可能不够保守。

要点

  • 治疗剂量依诺肝素后24小时,19例中11例抗Xa活性仍升高。
  • 10例抗Xa水平在预防峰值范围(0.2-0.5 IU/mL),1例仍在治疗峰值范围(0.5-1.0 IU/mL)。
  • 当前基于时间的ASRA推荐可能不够保守,需重新考虑抗Xa监测的价值。

核心结论

  • 治疗剂量依诺肝素后显著抗凝活性可能持续超过24小时,当前ASRA基于时间的推荐可能不够保守。
  • 需要进一步研究明确抗Xa活性低于何种水平可安全进行椎管内操作,但可能应重新考虑抗Xa监测的效用。

研究设计与样本

  • 评估择期手术患者抗Xa活性,几乎普遍符合ASRA抗凝指南(1例在23.25小时采血)。

主要发现

  • 19例患者中11例抗Xa活性升高。
  • 10例抗Xa水平在预防峰值范围(0.2-0.5 IU/mL),1例仍在治疗峰值范围(0.5-1.0 IU/mL)。

关键数值与推荐

  • ASRA指南推荐椎管内操作前治疗剂量依诺肝素(1 mg/kg每日两次或1.5 mg/kg每日一次)后至少间隔24小时。
  • 指南一贯不推荐对接受依诺肝素患者常规监测抗Xa水平。

临床怎么用

  • 临床实践中抗Xa水平在符合时间推荐的患者中仍常升高,提示需关注残留抗凝活性。
  • 可考虑在 available 时监测抗Xa水平以评估椎管内操作安全性。

局限性

  • 样本量小(19例),需进一步研究明确安全阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, the American Society of Regional Anesthesia and Pain Medicine (ASRA) anticoagulation guidelines recommend that before the performance of a neuraxial procedure a minimum of 24 hours should elapse following a treatment dose of enoxaparin (1 mg/kg twice daily or 1.5 mg/kg once daily). The guidelines have since their inception also consistently recommended against the routine use of anti-Xa level monitoring for patients receiving enoxaparin. However, we noted in our clinical practice that anti-Xa levels were frequently still elevated despite patients meeting the time-based recommendation for treatment dose enoxaparin. To further investigate the possibility that residual anticoagulant activity may persist longer than 24 hours after a treatment dose of enoxaparin, we assessed anti-Xa level activity in patients presenting for elective surgery. Despite nearly universal compliance with ASRA's anticoagulation guidelines (1 sample was drawn at 23.25 hours), anti-Xa activity was found to be elevated in 11 of 19 patients. While 10 patients had an anti-Xa level within the peak prophylactic range (0.2-0.5 IU/mL), 1 patient's level was found to still be in the peak therapeutic range (0.5-1.0 IU/mL). These findings suggest that significant anticoagulant activity may persist longer than previously appreciated after the last treatment dose of enoxaparin and that the current time-based ASRA recommendation may not be conservative enough. Further research is needed to delineate the level of anti-Xa activity below which it is likely safe to proceed with a neuraxial procedure, but it may be time to reconsider the utility of anti-Xa level monitoring when it is available.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Henshaw DS, Turner JD, Forest DJ, et al. Residual Enoxaparin Activity, Anti-Xa Levels, and Concerns About the American Society of Regional Anesthesia and Pain Medicine Anticoagulation Guidelines. Reg Anesth Pain Med. 2017. PMID: 28492441. doi:10.1097/AAP.0000000000000617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。